Matrix modulation and heart failure: new concepts question old beliefs

被引:24
作者
Deschamps, AM
Spinale, FG
机构
[1] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29403 USA
[2] Ralph H Johnson Vet Assoc Med Ctr, Charleston, SC USA
关键词
extracellular matrix; matrix metalloproteinase; myocardial remodeling;
D O I
10.1097/01.hco.0000162397.44843.83
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Myocardial remodeling is a complex process involving several molecular and cellular factors. Extracellular matrix has been implicated in the remodeling process. Historically, the myocardial extracellular matrix was thought to serve solely as a means to align cells and provide structure to the tissue. Although this is one of its important functions, evidence suggests that the extracellular matrix plays a complex and divergent role in influencing cell behavior. This paper characterizes some of the notable studies on this dynamic entity and on adverse myocardial remodeling that have been published over the past year, which further question the belief that the extracellular matrix is a static structure. Recent findings Progress has been made in understanding how the extracellular matrix is operative in the three major conditions (myocardial infarction, left ventricular hypertrophy due to overload, and dilated cardiomyopathy) that involve myocardial remodeling. Several studies have examined plasma profiles of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases following myocardial infarction and during left ventricular hypertrophy as surrogate markers of remodeling/remodeled myocardium. It has been demonstrated that bioactive signaling molecules and growth factors, proteases, and structural proteins influence cell-matrix interactions in the context of left ventricular hypertrophy. Finally, studies that either removed or added tissue inhibitor of metalloproteinases species in the myocardium demonstrated the importance of this regulatory protein in the remodeling process. Summary Understanding the cellular and molecular triggers that in turn give rise to changes in the extracellular matrix could provide opportunities to modify the remodeling process.
引用
收藏
页码:211 / 216
页数:6
相关论文
共 35 条
[1]   Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy [J].
Aso, N ;
Tamura, A ;
Nasu, M .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (11) :1468-1470
[2]  
BANFI C, 2004, EUR HEART J
[3]   Thrombospondins as matricellular modulators of cell function [J].
Bornstein, P .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (08) :929-934
[4]   Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy [J].
Bradham, WS ;
Gunasinghe, H ;
Holder, JR ;
Multani, M ;
Killip, D ;
Anderson, M ;
Meyer, D ;
Spencer, WH ;
Torre-Amione, G ;
Spinale, FG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (12) :2165-2173
[5]   Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart [J].
Collins, AR ;
Schnee, J ;
Wang, W ;
Kim, S ;
Fishbein, MC ;
Bruemmer, D ;
Law, RE ;
Nicholas, S ;
Ross, RS ;
Hsueh, WA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (09) :1698-1705
[6]   Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction [J].
Ducharme, A ;
Frantz, S ;
Aikawa, M ;
Rabkin, E ;
Lindsey, M ;
Rohde, LE ;
Schoen, FJ ;
Kelly, RA ;
Werb, Z ;
Libby, P ;
Lee, RT .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (01) :55-62
[7]   TIMP-3 deficiency leads to dilated cardiomyopathy [J].
Fedak, PWM ;
Smookler, DS ;
Kassiri, Z ;
Ohno, N ;
Leco, KJ ;
Verma, S ;
Mickle, DAG ;
Watson, KL ;
Hojilla, CV ;
Cruz, W ;
Weisel, RD ;
Li, RK ;
Khokha, R .
CIRCULATION, 2004, 110 (16) :2401-2409
[8]  
GunjaSmith Z, 1996, AM J PATHOL, V148, P1639
[9]   Long-term inhibition of rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice [J].
Hattori, T ;
Shimokawa, H ;
Higashi, M ;
Hiroki, J ;
Mukai, Y ;
Tsutsui, H ;
Kaibuchi, K ;
Takeshita, A .
CIRCULATION, 2004, 109 (18) :2234-2239
[10]   Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy [J].
Jayasankar, V ;
Woo, YJ ;
Bish, LT ;
Pirolli, TJ ;
Berry, MF ;
Burdick, J ;
Bhalla, RC ;
Sharma, RV ;
Gardner, TJ ;
Sweeney, HL .
CIRCULATION, 2004, 110 (11) :II180-II186